ActiveMSers Forums  

Go Back   ActiveMSers Forums > ActiveMSers.org Forums > General

Reply
 
Thread Tools Display Modes
  #1  
Old 06-15-2010, 01:02 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
 
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,753
Default Shrinkage: a brilliant reason to stay (or get) on therapy

The following study, to be published in the Journal of Neurology, tracked MSers of all types (RRMS, SPMS, PPMS, and even CIS) who were untreated. Now I don't like to get on my therapy soap box often—it's a personal decision each MSer needs to make, and I recognize that some of us cannot take or afford DMTs—but these results are eye opening. In every type of MS, they found that brain atrophy was "relentless." Food for thought when we have effective therapies that may slow this atrophy down. - Dave


Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, Korteweg T, Enzinger C, Fazekas F, Calabrese M, Dinacci D, Tedeschi G, Gass A, Montalban X, Rovira A, Thompson A, Comi G, Miller DH, Filippi M.

Quantitative Neuroimaging Laboratory, Department of Neurological and Behavioral Sciences, University of Siena, Viale Bracci 2, 53100 Siena, Italy.

OBJECTIVE: To assess the time course of brain atrophy and the difference across clinical subtypes in multiple sclerosis (MS). METHODS: The percent brain volume change (PBVC) was computed on existing longitudinal (2 time points) T1-weighted MRI from untreated (trial and nontrial) patients with MS. Patients (n = 963) were classified as clinically isolated syndromes suggestive of MS (CIS, 16%), relapsing-remitting (RR, 60%), secondary progressive (SP, 15%), and primary progressive (9%) MS. The median length of follow-up was 14 months (range 12-68).

RESULTS: There was marked heterogeneity of the annualized PBVC (PBVC/y) across MS subtypes (p = 0.003), with higher PBVC/y in SP than in CIS (p = 0.003). However, this heterogeneity disappeared when data were corrected for the baseline normalized brain volume. When the MS population was divided into trial and nontrial subjects, the heterogeneity of PBVC/y across MS subtypes was present only in the second group, due to the higher PBVC/y values found in trial data in CIS (p = 0.01) and RR (p < 0.001). The estimation of the sample sizes required for demonstrating a reduction of brain atrophy in patients in a placebo-controlled trial showed that this was larger in patients with early MS than in those with the progressive forms of the disease.

CONCLUSIONS: This first large study in untreated patients with multiple sclerosis (MS) with different disease subtypes shows that brain atrophy proceeds relentlessly throughout the course of MS, with a rate that seems largely independent of the MS subtype, when adjusting for baseline brain volume.
__________________
Dave Bexfield
ActiveMSers
Reply With Quote
  #2  
Old 06-15-2010, 07:08 PM
Lucia Lucia is offline
Optimistic Misfit
 
Join Date: Apr 2010
Posts: 38
Default

Good grief. I saw the word shrinkage and thought of something else and then thought....how can that be a good thing?

Sorry, long day.

Yes, good news for those who feel that DMD's had to be better than doing nothing.
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 02:29 PM.


Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.
ActiveMSers